Abstract:In this study, seven novel anthraquinones (1–7) and four described anthraquinones (8–11) were purified from Nicotiana tabacum-derived Aspergillus oryzae YNCA1220. It is worth noting that only analogs of 4 and 5 have been reported as natural products to date, while the nuclei of compounds 1–3, 6 and 7 were isolated for the first time in nature. Among them, compounds 1–3 bear an unusual anthra[2,3-b]furan-9,10-dione nucleus, 4 and 5 possess a rare 3-methyl-1H-pyrrol-2-yl substituent, and 6 and 7 are new framework anthraquinones bearing a 6-methyl-1,7-dihydro-2H-azepin-2-one ring. Interestingly, the in vivo assays indicated that 1, 4 and 5 had inactivation effects against tobacco mosaic virus (TMV) with inhibition rates of 41.6%, 55.4% and 38.6%, respectively, at a concentration of 50 μg/mL, which were better than that of the positive control agent, ningnanmycin (33.8%). Compounds 1, 4 and 5 also had protective effects with inhibition rates of 48.7%, 60.2% and 43.5% at the same concentration, while 4 had a better curative effect than ningnanmycin at a concentration of 100 μg/mL. In addition, mechanistic studies also revealed that a potent direct effect on TMV, the induction of SAR in tobacco plants, and the effective regulation of defense enzymes, defense genes, and defense hormones may be the reasons for the significant effects of 4 against TMV. At the same time, downregulation of the expression of total NtHsp70 protein by inhibiting the related Hsp70 genes may also be involved in tobacco resistance to TMV. To evaluate whether compounds have broader antiviral activities, the antirotavirus activities of new isolates were also evaluated and found to be highly effective with a therapeutic index (TI) value ranging from 11.6 to 17.7. This study suggests that the above anthraquinone compounds, particularly 4, have broad spectrum antiviral activities. The successful isolation and structure identification of the above anthraquinones provide new materials for the screening of anti-TMV agents and contribute to the improved utilization of N. tabacum-derived fungi.

Antiviral Phenolic Compounds from Arundina Gramnifolia

Phenolic constituents from Parakmeria yunnanensis and their anti-HIV-1 activity

Extraction and characterization of anti-virus anthraquinones from Nicotiana tabacum-derived Aspergillus oryzae YNCA1220

New Lignans from the Leaves and Stems of Schisandra chinensis and Their Anti‐HIV‐1 Activities

Five quinolizidine alkaloids with anti-tobacco mosaic virus activities from two species of Sophora

Synthesis and Biological Activity of Novel Oxazinyl Flavonoids as Antiviral and Anti-Phytopathogenic Fungus Agents

Design, synthesis, and antiviral activities of myricetin derivatives containing pyridazinone

Design, synthesis, and antiviral activities of Myricetin derivatives containing Phenoxypyridine

Two New Anti-Tobacco Mosaic Virus Quinoline Alkaloids from the Stems of Nicotiana tabacum

Bioactive Phenolics and Terpenoids from Manglietia Insignis.

Two New Stilbenes from the Whole Plant of Arundina graminifolia and Their Anti-SARS-CoV-2 Activity

Anti-TMV activity and effects of three prieurianin-type limonoids from Munronia henryi

Myricetin derivatives containing the benzoxazinone moiety discovered as potential anti-tobacco mosaic virus agents

Alatains A and B, unique hetero-dimeric polyphenols from Cassia alata and their anti-tobacco mosaic virus activity

Antiviral Activities of Novel Myricetin Derivatives Containing 1,3,4‐Oxadiazole Bisthioether

Synthesis and antiviral bioactivity of novel 3-((2-((1E,4E)-3-oxo-5-arylpenta-1,4-dien-1-yl)phenoxy)methyl)-4(3H)-quinazolinone derivatives.

Anti-TMV activity and mode of action of three alkaloids isolated from Chelidonium majus

Anti-influenza virus polyketides from the acid-tolerant fungus Penicillium purpurogenum JS03-21

Flavonol Derivatives Containing a Quinazolinone Moiety: Design, Synthesis, and Antiviral Activity

Furan-2-Carboxylic Acids from the Roots of Nicotiana tabacum and their Bioactivities

Novel flavonol derivatives containing benzoxazole as potential antiviral agents: design, synthesis, and biological evaluation